The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Earlier use of cilta-cel is associated with better immune fitness in multiple myeloma: CARTITUDE-4
Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY,
discusses the CARTITUDE-4 study (NCT04181827), which investigated the earlier use of ciltacabtagene autoleucel (cilta-cel) for multiple myeloma. He highlights findings showing that earlier use of cilta-cel is associated with better immune fitness and stronger immune effects, as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
